GlaxoSmithKline annual profit rises 36%; warns of earnings decline in 2019

Writer, Stock Market Wire
Wednesday, February 6, 2019 - 13:12

GlaxoSmithKline posted a 36% rise in pre-tax profit, underpinned higher sales of its shingles vaccine and respiratory disease treatments, but warned of lower earnings in 2019.

Pre-tax profit for the year through December rose to £4.80bn, as sales climbed 2% to £30.82bn, or by 5% on a constant currency basis.

Adjusted earnings per share rose 7% to 119.4p, or by 12% on a constant currency basis, assisted by improved operating margin and continued financial efficiencies, the company said.

For 2019, GlaxoSmithKline forecast EPS to decline by 5-9% in constant currency, reflecting recent approval of a generic competitor to respiratory disease treatment Advair in the US.

The guidance also reflected the expected impact of the recent Tesaro acquisition and assumed the consumer healthcare disposal and JV with Pfizer was completed to plan.

In 2018, shingles vaccine sales more than doubled to £784m, while total new respiratory product sales rose 35% to £2.6bn.

GlaxoSmithKline declared a full-year dividend of 80p a share, which it forecast to remain flat in 2019.

'GSK delivered improved operating performance in 2018 with group sales growth, strong commercial execution of new product launches, especially Shingrix, continued cost discipline and better cash generation,' chief executive Emma Walmsley said.

At 1:12pm: (LON:GSK) GlaxoSmithKline PLC share price was +10.8p at 1533.4p


Related content

Broker Forecast - UBS issues a broker note on GlaxoSmithKline PLC

UBS today upgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to buy (from neutral) and raised its price target to 1900p (from 1610p).

Broker Forecasts...

Thu, 21/11/2019 - 09:50


Four stocks priced for perfection and likely to disappoint investors

Author: 

Controversial Brexiteer hedge fund manager Crispin Odey is fond of saying that cycles never die, or what goes up inevitably comes back down. What this...

Thu, 14/11/2019 - 00:00


Broker Forecast - Liberum Capital issues a broker note on GlaxoSmithKline PLC

Liberum Capital today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1890p (from 1510p).

Broker Forecasts data provided...

Mon, 04/11/2019 - 10:30


Broker Forecast - Barclays Capital issues a broker note on GlaxoSmithKline PLC

Barclays Capital today reaffirms its equal weight investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1650p (from 1600p).

Broker Forecasts data...

Fri, 01/11/2019 - 10:10


Broker Forecast - DZ Bank issues a broker note on GlaxoSmithKline PLC

DZ Bank today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 2000p (from 1850p).

Broker Forecasts data provided...

Thu, 31/10/2019 - 09:50